Mylan Pharmaceuticals Receives Final FDA Report and Reaffirms Its 48-Year Exemplary Record ...(company maintains one of the industry's ...),Health

Date:8/13/2009

company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.

'/>"/>

SOURCE Mylan Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related medicine news :

1. President Clinton and Mylan Chairman and CEO Robert J. Coury Announce New Agreement to Lower Price of Treatment for Patients with Drug-Resistant HIV in Developing Countries
2. Mylan Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Closing Bell
3. Mylan Announces Enhancements to Executive Management Team
4. Mylan Reports That the FDA Determined That All Accusations Were Unfounded
5. Mylan Reiterates and Stands Behind Its 48-Year Commitment and Track Record of Quality
6. Mylan Receives FDA Approval for Additional Strengths of the Antipsychotic Haloperidol
7. Mylan Declares Quarterly Preferred Stock Dividend
8. Mylan Receives FDA Approval for Generic Version of Thyroid Deficiency Treatment Cytomel(R)
9. Mylan Schedules Second Quarter 2009 Financial Results Conference Call and Live Webcast
10. Mylan Receives FDA Approval for Additional Strength of Generic Restoril(R)
11. Mylans Chief Operating Officer Heather Bresch to Testify Before Congress Concerning Patent Settlements Between Brand and Generic Pharmaceutical Companies and Tactics That Delay Market Entry of High Quality, Affordable Generic Drugs